Concepedia

Richard Zang

RZ

14

Publications

1.2K

Citations

13

H-Index

2012

Active since

Affiliations

Novartis (United States)(Current)

Genomics Institute of the Novartis Research Foundation

Novartis (Switzerland)

Novartis Institutes for BioMedical Research

WuXi AppTec (China)

Richard Zang is an author at Novartis (United States) specializing in medicine, drug discovery, and tumor biology.

Top concepts

Publications per year

2012–2023

14

Publications

14

Antibody Conjugation of a Chimeric BET Degrader Enables <i>in vivo</i> Activity

Thomas H. Pillow, Pragya Adhikari, Robert A. Blake et al. · ChemMedChem · 2019 · 178 citations

An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance

Thijs J. Hagenbeek, Marc Hafner, Rana Mroue et al. · Nature Cancer · 2023 · 169 citations · Full text

Small Molecule Dysregulation of TEAD Lipidation Induces a Dominant-Negative Inhibition of Hippo Pathway Signaling

Jeffrey K. Holden, James J. Crawford, Cameron L. Noland et al. · Cell Reports · 2020 · 160 citations · Full text

, , +17

Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers

Pablo D. García, John L. Langowski, Yingyun Wang et al. · Clinical Cancer Research · 2014 · 110 citations · Full text

Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα)

Peter S. Dragovich, Pragya Adhikari, Robert A. Blake et al. · Bioorganic & Medicinal Chemistry Letters · 2019 · 102 citations

, , +9

Rows per page

1–5 of 14